MA30202B1 - Composes organiques - Google Patents
Composes organiquesInfo
- Publication number
- MA30202B1 MA30202B1 MA30987A MA30987A MA30202B1 MA 30202 B1 MA30202 B1 MA 30202B1 MA 30987 A MA30987 A MA 30987A MA 30987 A MA30987 A MA 30987A MA 30202 B1 MA30202 B1 MA 30202B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- diseases
- formula
- treatment
- insulin resistance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les composés de formule sont des inhibiteurs des protéines tyrosines phosphatases (PTPases) et, ainsi, peuvent être employés pour le traitement de maladies provoquées par l'intermédiaire de l'activité de la PTPase. Les composés de la présente invention peuvent également être employés en tant qu'inhibiteurs d'autres enzymes caractérisés par une région de liaison à la phosphotyrosine tel que le domaine SH2. De même, les composés de formule (I) peuvent être employés pour la prévention et/ou le traitement de la résistance à l'insuline associée à l'obésité, de l'intolérance au glucose, du diabète sucré, de l'hypertension et des maladies ischémiques des grands et des petits vaisseaux sanguins, des maladies qui accompagnent le diabète de type 2, y compris l'hyperlipidémie, l'hypertriglycéridémie, l'athérosclérose, la resténose vasculaire, le syndrome du côlon irritable, la pancréatite, les tumeurs et carcinomes cellulaires adipeux tels que le liposarcome, la dyslipidémie et les autres troubles au cours desquels une résistance à l'insuline est indiquée. De plus, les composés de la présente invention peuvent être employés pour traiter et/ou prévenir le cancer (tel que le cancer de la prostate ou du sein), l'ostéoporose, les maladies neurodégénératives et infectieuses, et les maladies impliquant une inflammation ainsi que le système immunitaire.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74857305P | 2005-12-08 | 2005-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30202B1 true MA30202B1 (fr) | 2009-02-02 |
Family
ID=37950917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30987A MA30202B1 (fr) | 2005-12-08 | 2008-06-02 | Composes organiques |
Country Status (26)
Country | Link |
---|---|
US (1) | US7700633B2 (fr) |
EP (1) | EP1963292B1 (fr) |
JP (1) | JP2009519248A (fr) |
KR (1) | KR20080074969A (fr) |
CN (1) | CN101326173A (fr) |
AR (1) | AR056838A1 (fr) |
AT (1) | ATE546440T1 (fr) |
AU (1) | AU2006321905B2 (fr) |
BR (1) | BRPI0619600A2 (fr) |
CA (1) | CA2629857A1 (fr) |
CR (1) | CR10049A (fr) |
EC (1) | ECSP088506A (fr) |
ES (1) | ES2381280T3 (fr) |
IL (1) | IL191549A0 (fr) |
MA (1) | MA30202B1 (fr) |
NO (1) | NO20083031L (fr) |
NZ (1) | NZ568243A (fr) |
PE (2) | PE20100733A1 (fr) |
PL (1) | PL1963292T3 (fr) |
PT (1) | PT1963292E (fr) |
RU (1) | RU2008127254A (fr) |
TN (1) | TNSN08249A1 (fr) |
TW (1) | TW200732315A (fr) |
UA (1) | UA94724C2 (fr) |
WO (1) | WO2007067615A2 (fr) |
ZA (1) | ZA200804074B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2397177T3 (es) * | 2005-12-08 | 2013-03-05 | Novartis Ag | Derivados de 1,2,5-tiazolidina útiles para el tratamiento de condiciones mediadas por proteínas tirosina fosfatasas (PTPASA) |
BRPI0619547A2 (pt) * | 2005-12-08 | 2011-10-04 | Novartis Ag | 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas |
UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
WO2008067527A1 (fr) * | 2006-12-01 | 2008-06-05 | Novartis Ag | Inhibiteurs de la protéine tyrosine phosphatase pour le traitement d'une atrophie musculaire et de troubles associés |
AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
WO2012046869A1 (fr) | 2010-10-08 | 2012-04-12 | 持田製薬株式会社 | Dérivé d'amide cyclique |
US9072758B2 (en) | 2011-04-28 | 2015-07-07 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
CN113365992B (zh) * | 2018-12-21 | 2024-05-28 | 晶体制药独资有限公司 | 用于沃塞洛托的制备的方法和中间体 |
MX2021010544A (es) * | 2019-03-14 | 2021-10-01 | Calico Life Sciences Llc | Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos. |
GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
JP2023508914A (ja) * | 2019-12-20 | 2023-03-06 | カリコ ライフ サイエンシーズ エルエルシー | プロテインチロシンホスファターゼ分解剤及びその使用方法 |
CA3211545A1 (fr) * | 2021-03-11 | 2022-09-15 | Liansheng Li | Heterocycles et leurs utilisations |
AU2022387106A1 (en) * | 2021-11-11 | 2024-05-23 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
WO2023150150A1 (fr) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
WO2023150523A1 (fr) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
WO2023150535A1 (fr) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
WO2024059041A1 (fr) * | 2022-09-13 | 2024-03-21 | Kumquat Biosciences, Inc. | N-hétérocycles benzo-fusionnés et leurs utilisations |
WO2024067802A1 (fr) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | Inhibiteur de protéine tyrosine phosphatase, son procédé de préparation et son utilisation pharmaceutique |
CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646508A (zh) * | 2002-04-03 | 2005-07-27 | 诺瓦提斯公司 | 作为ptp酶1b抑制剂的5-取代的1,1-二氧代-1,2,5-噻二唑烷-3-酮衍生物 |
GB0225986D0 (en) | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
EP1594497B1 (fr) * | 2002-12-30 | 2009-05-27 | Vertex Pharmaceuticals Incorporated | Sulfhydantoines utilisees comme isosteres phosphate |
WO2005035551A2 (fr) * | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibiteurs de proteines se liant a des molecules phosphorylees |
BRPI0619547A2 (pt) * | 2005-12-08 | 2011-10-04 | Novartis Ag | 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas |
ES2397177T3 (es) * | 2005-12-08 | 2013-03-05 | Novartis Ag | Derivados de 1,2,5-tiazolidina útiles para el tratamiento de condiciones mediadas por proteínas tirosina fosfatasas (PTPASA) |
US8084448B2 (en) * | 2006-03-31 | 2011-12-27 | Novartis Ag | Organic compounds |
-
2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 EP EP06839094A patent/EP1963292B1/fr active Active
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 CA CA002629857A patent/CA2629857A1/fr not_active Abandoned
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/fr active Application Filing
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Application Discontinuation
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
-
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL1963292T3 (pl) | 2012-07-31 |
ZA200804074B (en) | 2009-03-25 |
TNSN08249A1 (en) | 2009-10-30 |
AR056838A1 (es) | 2007-10-24 |
ES2381280T3 (es) | 2012-05-24 |
JP2009519248A (ja) | 2009-05-14 |
PE20100733A1 (es) | 2010-10-29 |
BRPI0619600A2 (pt) | 2011-10-11 |
IL191549A0 (en) | 2008-12-29 |
ECSP088506A (es) | 2008-07-30 |
US7700633B2 (en) | 2010-04-20 |
KR20080074969A (ko) | 2008-08-13 |
PT1963292E (pt) | 2012-05-10 |
NO20083031L (no) | 2008-08-28 |
NZ568243A (en) | 2011-07-29 |
WO2007067615A3 (fr) | 2007-11-15 |
CA2629857A1 (fr) | 2007-06-14 |
EP1963292A2 (fr) | 2008-09-03 |
PE20071031A1 (es) | 2007-11-15 |
AU2006321905A1 (en) | 2007-06-14 |
CN101326173A (zh) | 2008-12-17 |
ATE546440T1 (de) | 2012-03-15 |
AU2006321905B2 (en) | 2011-08-11 |
RU2008127254A (ru) | 2010-01-20 |
CR10049A (es) | 2008-08-25 |
US20080262050A1 (en) | 2008-10-23 |
TW200732315A (en) | 2007-09-01 |
EP1963292B1 (fr) | 2012-02-22 |
WO2007067615A2 (fr) | 2007-06-14 |
UA94724C2 (en) | 2011-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30202B1 (fr) | Composes organiques | |
MA30018B1 (fr) | Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase | |
Fleming et al. | The tissue renin–angiotensin system and intracellular signalling | |
TNSN08247A1 (en) | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
WO2007115058A3 (fr) | Composés organiques | |
Seno et al. | Pyrrolidine inhibitors of human cytosolic phospholipase A2 | |
Rosini et al. | Rational approach to discover multipotent anti-Alzheimer drugs | |
Marmorstein | Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases | |
MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
MA31862B1 (fr) | Anticorps anti-mésothéline et leurs utilisations | |
MA32887B1 (fr) | Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
Hamid et al. | Role of kinins in hypertension and heart failure | |
NO20054769L (no) | Substituerte fenylalkansyrer | |
MA27548A1 (fr) | Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete. | |
MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
MA30975B1 (fr) | Formulation parenterale d'anticorps anti-peptide abeta | |
MA29915B1 (fr) | Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
MA32928B1 (fr) | Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer | |
MA32099B1 (fr) | Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci | |
MA30762B1 (fr) | Anticorps specifiques du prlr et leurs utilisations | |
WO2006055525A3 (fr) | Inhibiteurs de proteine-tyrosine-phosphatase et methodes d'utilisation de ceux-ci | |
BR0308974A (pt) | Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b |